Xbrane Biopharma AB (XBRANE) — Cash Flow-to-Debt Ratio
Xbrane Biopharma AB (XBRANE) has a Cash Flow-to-Debt Ratio of -0.61x as of December 2025, meaning its operating cash flow of Skr-67.56 Million could theoretically repay -1% of its total liabilities (Skr110.97 Million) in one year. See Xbrane Biopharma AB free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Xbrane Biopharma AB Cash Flow-to-Debt Ratio (2013–2025)
Historical debt coverage capacity for Xbrane Biopharma AB across 13 annual periods. Also explore net asset momentum of Xbrane Biopharma AB to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Xbrane Biopharma AB (2013–2025)
Year-by-year debt coverage analysis for Xbrane Biopharma AB. For market capitalisation and broader financial context, see Xbrane Biopharma AB market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.26x | Skr-250.69 Million | Skr110.97 Million | ▼ -970.8% |
| 2024 | -0.21x | Skr-133.73 Million | Skr633.89 Million | ▲ +75.0% |
| 2023 | -0.84x | Skr-406.68 Million | Skr482.17 Million | ▼ -15.5% |
| 2022 | -0.73x | Skr-193.92 Million | Skr265.63 Million | ▲ +14.7% |
| 2021 | -0.86x | Skr-219.61 Million | Skr256.69 Million | ▲ +26.1% |
| 2020 | -1.16x | Skr-238.41 Million | Skr206.06 Million | ▼ -20.4% |
| 2019 | -0.96x | Skr-148.59 Million | Skr154.62 Million | ▼ -449.4% |
| 2018 | 0.28x | Skr46.71 Million | Skr169.81 Million | ▲ +116.8% |
| 2017 | -1.63x | Skr-36.85 Million | Skr22.55 Million | ▲ +55.2% |
| 2016 | -3.65x | Skr-39.43 Million | Skr10.81 Million | ▼ -719.3% |
| 2015 | -0.45x | Skr-12.39 Million | Skr27.82 Million | ▲ +93.5% |
| 2014 | -6.83x | Skr-2.67 Million | Skr390.70K | ▼ -57.1% |
| 2013 | -4.35x | Skr-2.20 Million | Skr505.44K | — |